IRMDIRADIMED
Is it safe?
Solid, nothing alarming. No accounting flags, quality moderate.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$123K, 90 days to Oct 22, 2026), selling is often routine.
Moderate price swings, typical volatility. Worst drawdown -64% · now 18% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can IRMD take a bad year?
The deepest fall in IRMD's price history on file is −64%; it is 18% below its high today.
Worst drawdown on file · −18% today
- Annualised volatility
- 33%
Annualised volatility · S&P 500 16% · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $59M
- EBITDA, trailing twelve months
- $29M
- Operating profit, trailing twelve months
- $28M
- Annualised volatilitytwo years of daily moves
- 33%
- Worst drawdown on file
- −64%
- Below its 52-week high
- 18%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.